會(huì)員.png)
15
AML-193細(xì)胞， 人急性單核細(xì)胞白血病單核細(xì)胞
| ATCC® Number: | CRL-9589™ | Price: | |
| Designations:AML-193Depositors:Wistar InstituteBiosafety Level:1 AML-193細(xì)胞， 人急性單核細(xì)胞白血病單核細(xì)胞Shipped:frozenMedium & Serum:See PropagationGrowth Properties:suspensionOrganism:Homo sapiensMorphology:lymphoblast Source:Organ: peripheral blood Disease: acute monocytic leukemia Cell Type: monocyte;Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimay responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.Antigen Expression:CD15, human; Homo sapiens, expressed (75 to 95% of the cells) (75 to 95% of the cells)DNA Profile (STR):Amelogenin: X CSF1PO: 11,12 D13S317: 12 D16S539: 12 D5S818: 9,13 D7S820: 9,12 THO1: 7,9 TPOX: 8,9 vWA: 15,17Cytogenetic Analysis:This is a hyperdiploid human cell line. The modal chromosome number is 49, occurring in 50% of cells. The rate of polyploidy is 2.2%. There is one marker chromosome, der(17)t(17;17)(p13.1;q21.3), that occurred in every cell. These cells are trisomic for N3, N6, N8, and N13, and occasionally also for N2. N17 and X chromosome had a single copy, but occasionally the X had two copies. Thus the modal karyotype of this cell line is 49, X, +3, +6, +8, +der(17)t(17;17)(p13.1;q21.3), -17. The subline with 50, X, +2, +3, +6, +8, +der(17)t(17;17)(p13.1;q21.3), -17 and 50, XX, +3, +6, +8, +der(17)t(17;17)(p13.1;q21.3, -17 also occurred, but at a very low frequency.Age:13 yearsGender:female 單核細(xì)胞Comments:Interleukin-3 (interleukin 3, IL-3) and granulocyte/macrophage colony stimulating factor (GM-CSF) act synergistically to stimulate growth of the cells. Granulocyte colony stimulating factor (G-CSF) also supports short term and long term growth of AML-193 cells and acts synergistically with GM-CSF in inducing proliferation of the cells.This line was formerly designated ATCC HTB-188.Propagation:ATCC complete growth medium: Iscove's modified Dulbecco's medium with 0.005 mg/ml insulin, 0.005 mg/ml transferrin and 5 ng/ml GM-CSF, 95%; fetal bovine serum, 5%.Temperature: 37.0°C Growth Conditions: The cells are dependent upon GM-CSF for long term growth. Conditioned medium from U-87MG (ATCC HTB-14) may be used at a concentration of 10% to replace the GM-CSF in the medium (see J. Immunol. 139:3348- 3354, 1987).Subculturing:Protocol: Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 3 X 10(5) cells/ml and maintain between 3 X 10(5) and 1 X 10(6) cells/ml. Medium Renewal: Every 2 to 3 daysPreservation:Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phaseRelated Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2005recommended serum:ATCC 30-2020References:22617: Lange B, et al. Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines. Blood 70: 192-199, 1987. PubMed: 349613223467: Santoli D, et al. Synergistic and antagonistic effects of recombinant human interleukin (IL) 3, IL-1 alpha, granulocyte and macrophage colony-stimulating factors (G-CSF and M-CSF) on the growth of GM-CSF-dependent leukemic cell lines. J. Immunol. 139: 3348-3354, 1987. PubMed: 3500218 | |||
